1
|
Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJT, van 't Veer LJ. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010; 21:717-722. [PMID: 19825882 DOI: 10.1093/annonc/mdp388] [Citation(s) in RCA: 119] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | | | - B Kreike
- Department of Radiation Oncology, The Netherlands Cancer Institute
| | | | | | | | | | - E J T Rutgers
- Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | | |
Collapse
|
2
|
Bollet M, Servant N, Kreike B, Halfwerk H, Daoud S, Lebigot I, Bartelink H, Fourquet A, Sigal-Zafrani B, van de Vijver M. 114 Validation process of a gene-expression signature of local recurrences after breast-conserving treatments. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70145-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
3
|
Turner N, Turner N, Lambros M, Horlings H, Horlings H, Pearson A, Sharpe R, Mackay A, Natrajan R, Geyer F, van Kouwenhove M, Kreike B, Ashworth A, van de Vijver M, van de Vijver M, Reis-Filho J. Integrative Molecular Profiling of Triple Negative Breast Cancers Identifies Potential Therapeutic Targets Including Amplifications of FGFR2. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple negative breast cancers (TNBCs) have a relatively poor prognosis emphasising the need to identify new subtype specific target therapies. Based on the concept of oncogene addiction, we searched for potential therapeutic targets by identifying genes consistently over-expressed when amplified in TNBC. Fifty six TNBCs were subjected to high resolution tiling path microarray-based comparative genomic hybridisation (aCGH); out of these cases, 24 were also subjected to genome-wide microarray-based mRNA expression analysis. TNBCs showed a high level of genetic instability, with recurrent regions of amplification (>4 copies) included multiple regions on 1q and 8q, 3q25, 10p14, 10q26, 13q34, 15q26 and 19q12-19q13. Integration of aCGH and expression data revealed 38 genes that were significantly overexpressed when amplified. This list includes known oncogenes and potential therapeutic targets, such as MCL1 (1q21.2), FGFR2 (10q26.3), BUB3 (10q26.3), RAB20 (13q34), PKN1 (19p13.12), and NOTCH3 (19p13.12). To validate FGFR2 as a therapeutic target, we screened a panel of cell lines, by western blotting and aCGH, and identified two TNBC cell lines with FGFR2 amplification. In these cell lines FGFR2 was constitutively active in a ligand independent manner, and RNA interference-mediated silencing of FGFR2 selectively decreased survival of cell lines harbouring FGFR2 amplification. Likewise FGFR2 amplified cell lines were highly sensitive to FGFR tyrosine kinase inhibitor PD173074 (IC50 <20nM). Treatment with PD173074 induced apoptosis in amplified cell lines, as did treatment with PI3 kinase inhibitors LY294002 and BEZ-235 suggesting that apoptosis resulted from inhibition of AKT signalling. Examination of publically available CGH data sets confirmed FGFR2 amplification in 4% (5/124 95%CI 1.3-9.2%) of TNBC, with no cases of FGFR2 amplification in other subtypes (0/150, p=0.02). Our results suggest that FGFR2 amplification is a therapeutic target in a small subset of TNBCs.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3147.
Collapse
Affiliation(s)
- N. Turner
- 1The Institute of Cancer Research, United Kingdom
| | - N. Turner
- 2Royal Marsden Hospital NHS Trust, United Kingdom
| | - M. Lambros
- 1The Institute of Cancer Research, United Kingdom
| | | | - H. Horlings
- 4The Netherlands Cancer Institute, The Netherlands
| | - A. Pearson
- 1The Institute of Cancer Research, United Kingdom
| | - R. Sharpe
- 1The Institute of Cancer Research, United Kingdom
| | - A. Mackay
- 1The Institute of Cancer Research, United Kingdom
| | - R. Natrajan
- 1The Institute of Cancer Research, United Kingdom
| | - F. Geyer
- 1The Institute of Cancer Research, United Kingdom
| | | | - B. Kreike
- 4The Netherlands Cancer Institute, The Netherlands
| | - A. Ashworth
- 1The Institute of Cancer Research, United Kingdom
| | | | | | | |
Collapse
|
4
|
Wesseling J, Hartog H, Horlings H, van der Vegt B, Ajouaou A, Kreike B, van de Vijver M, de Bock GH, Boezen M, van der Graaf WT. Different effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple-negative invasive ductal breast carcinoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3546 Background: The insulin-like growth factor type 1 receptor (IGF-1R) is involved in progression and sensitivity to systemic treatment of breast cancer. Moreover, targeted inhibition of IGF-1R is likely to be beneficial in systemic treatment. However, it is unknown how to select patients for IGF-1R targeted therapy. Therefore, we studied the relation between IGF-1R expression and prognosis in invasive ductal breast carcinomas. Methods: Immunohistochemistry was performed on tumor tissue of a consecutive cohort of 429 female patients treated for operable primary invasive ductal breast carcinoma. TMA sections were stained with antibodies against IGF1-R, insulin receptor (IR), ER, PR, HER-2, epidermal growth factor receptor (EGFR) and phosphorylated-Akt (p-Akt). Cytoplasmic and membranous IGF-1R staining were scored separately, as the relevance of IGF-1R cellular localization is yet unknown. Associations between IGF-1R expression with clinical and tumor characteristics were evaluated in a multivariate Cox regression model. To study in more detail the prognostic role of IGF-1R expression in triple negative invasive ductal carcinomas (TN IDCs), 51 TN IDCs from the series described above were combined with 64 TN IDCs from an independent dataset with similar patient and clinico-pathological characteristics. Results: Patients with tumors expressing both ER and cytoplasmic IGF-1R have a longer disease free survival (HR = 0.20; 95% CI 0.07 - 0.63; p-value = 0.006) and breast cancer specific survival (HR = 0.20, 95% CI 0.07 - 0.63, p-value = 0.002), independent of other known prognostic factors. Conversely, in the combined series of 105 TN IDCs, cytoplasmic IGF-1R expression was associated with a shorter disease free survival (HR = 2.29; 95% CI 1.08 - 4.48, p-value = 0.03). In a multivariate model including known prognostic factors, cytoplasmic IGF-1R expression was nearly significantly related to a shorter disease free survival (HR 2.06; 95% CI 0.95 - 4.47; p = 0.07). Conclusions: The favorable versus unfavorable association with prognosis of IGF-1R expression in ER positive versus TN IDCs may provide new opportunities to select patients for IGF-1R targeted therapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Wesseling
- Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Groningen, Groningen, Netherlands; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
| | - H. Hartog
- Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Groningen, Groningen, Netherlands; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
| | - H. Horlings
- Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Groningen, Groningen, Netherlands; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
| | - B. van der Vegt
- Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Groningen, Groningen, Netherlands; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
| | - A. Ajouaou
- Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Groningen, Groningen, Netherlands; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
| | - B. Kreike
- Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Groningen, Groningen, Netherlands; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
| | - M. van de Vijver
- Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Groningen, Groningen, Netherlands; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
| | - G. H. de Bock
- Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Groningen, Groningen, Netherlands; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
| | - M. Boezen
- Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Groningen, Groningen, Netherlands; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
| | - W. T. van der Graaf
- Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Groningen, Groningen, Netherlands; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
| |
Collapse
|
5
|
Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LFA, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216:141-50. [PMID: 18720457 DOI: 10.1002/path.2407] [Citation(s) in RCA: 411] [Impact Index Per Article: 25.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Most invasive breast cancers are classified as invasive ductal carcinoma not otherwise specified (IDC NOS), whereas about 25% are defined as histological 'special types'. These special-type breast cancers are categorized into at least 17 discrete pathological entities; however, whether these also constitute discrete molecular entities remains to be determined. Current therapy decision-making is increasingly governed by the molecular classification of breast cancer (luminal, basal-like, HER2+). The molecular classification is derived from mainly IDC NOS and it is unknown whether this classification applies to all histological subtypes. We aimed to refine the breast cancer classification systems by analysing a series of 11 histological special types [invasive lobular carcinoma (ILC), tubular, mucinous A, mucinous B, neuroendocrine, apocrine, IDC with osteoclastic giant cells, micropapillary, adenoid cystic, metaplastic, and medullary carcinoma] using immunohistochemistry and genome-wide gene expression profiling. Hierarchical clustering analysis confirmed that some histological special types constitute discrete entities, such as micropapillary carcinoma, but also revealed that others, including tubular and lobular carcinoma, are very similar at the transcriptome level. When classified by expression profiling, IDC NOS and ILC contain all molecular breast cancer types (ie luminal, basal-like, HER2+), whereas histological special-type cancers, apart from apocrine carcinoma, are homogeneous and only belong to one molecular subtype. Our analysis also revealed that some special types associated with a good prognosis, such as medullary and adenoid cystic carcinomas, display a poor prognosis basal-like transcriptome, providing strong circumstantial evidence that basal-like cancers constitute a heterogeneous group. Taken together, our results imply that the correct classification of breast cancers of special histological type will allow a more accurate prognostication of breast cancer patients and facilitate the identification of optimal therapeutic strategies.
Collapse
Affiliation(s)
- B Weigelt
- Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|